PL2624859T3 - Czynnik ii samodzielnie lub w skojarzeniu z dalszymi czynnikami do leczenia zaburzeń hemostazy powiązanych z koagulopatią z rozcieńczenia - Google Patents

Czynnik ii samodzielnie lub w skojarzeniu z dalszymi czynnikami do leczenia zaburzeń hemostazy powiązanych z koagulopatią z rozcieńczenia

Info

Publication number
PL2624859T3
PL2624859T3 PL11761051T PL11761051T PL2624859T3 PL 2624859 T3 PL2624859 T3 PL 2624859T3 PL 11761051 T PL11761051 T PL 11761051T PL 11761051 T PL11761051 T PL 11761051T PL 2624859 T3 PL2624859 T3 PL 2624859T3
Authority
PL
Poland
Prior art keywords
alone
factor
treatment
combination
further factors
Prior art date
Application number
PL11761051T
Other languages
English (en)
Inventor
Ann Lovgren
Kenny Hansson
Original Assignee
Medimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2624859(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Limited filed Critical Medimmune Limited
Publication of PL2624859T3 publication Critical patent/PL2624859T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL11761051T 2010-10-06 2011-09-19 Czynnik ii samodzielnie lub w skojarzeniu z dalszymi czynnikami do leczenia zaburzeń hemostazy powiązanych z koagulopatią z rozcieńczenia PL2624859T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39022410P 2010-10-06 2010-10-06

Publications (1)

Publication Number Publication Date
PL2624859T3 true PL2624859T3 (pl) 2017-09-29

Family

ID=44677879

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11761051T PL2624859T3 (pl) 2010-10-06 2011-09-19 Czynnik ii samodzielnie lub w skojarzeniu z dalszymi czynnikami do leczenia zaburzeń hemostazy powiązanych z koagulopatią z rozcieńczenia

Country Status (16)

Country Link
US (1) US9433664B2 (pl)
EP (1) EP2624859B1 (pl)
JP (1) JP6000259B2 (pl)
KR (1) KR20130136988A (pl)
CN (1) CN103221061A (pl)
AU (1) AU2011313505B2 (pl)
BR (1) BR112013008034A2 (pl)
CA (1) CA2812888A1 (pl)
DK (1) DK2624859T3 (pl)
ES (1) ES2625153T3 (pl)
HU (1) HUE033204T2 (pl)
MX (1) MX343784B (pl)
PL (1) PL2624859T3 (pl)
RU (1) RU2606155C2 (pl)
SG (2) SG10201508159SA (pl)
WO (1) WO2012045569A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6000259B2 (ja) 2010-10-06 2016-09-28 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 止血障害治療用第ｉｉ因子およびフィブリノーゲン
IL230150A0 (en) 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing zymogens
AU2018217375B2 (en) * 2017-02-09 2024-04-18 Csl Behring Gmbh A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
CN116059431A (zh) * 2021-10-29 2023-05-05 丁琴琴 一种含凝血因子的双层止血敷料及其制备方法
WO2023220412A1 (en) * 2022-05-13 2023-11-16 Cedars-Sinai Medical Center Hemostatic monitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002105A1 (en) * 1980-01-28 1981-08-06 Baxter Travenol Lab Therapeutic compositions & methods for manufacture and use
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
DE4430204A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
DE59712322D1 (de) * 1996-03-20 2005-06-30 Baxter Ag Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
US7094428B2 (en) 2000-06-16 2006-08-22 The University Of Medicine And Dentistry Of New Jersey Hemostatic compositions, devices and methods
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
KR20030088430A (ko) 2001-02-05 2003-11-19 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드 및 인자 ⅸ 폴리펩티드의 조합 사용
US20060025336A1 (en) 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
RU2298416C2 (ru) * 2001-07-20 2007-05-10 Ново Нордиск Хелт Кэр Аг Фармацевтическая композиция, содержащая полипептиды фактора vii и полипептиды фактора xi
US20040101546A1 (en) * 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
EP1587424A4 (en) 2002-12-31 2012-01-25 Marinepolymer Tech Inc Bleeding Compounds and their uses
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ES2399277T3 (es) 2004-05-27 2013-03-27 Baxter International Inc. Procedimiento de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados
WO2006114105A2 (en) 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
CN101501216B (zh) * 2006-03-06 2013-10-02 胡玛基因公司 制备重组人凝血酶的方法
US20080014251A1 (en) 2006-07-14 2008-01-17 Advanced Vascular Dynamics Hemostatic compound and its use
US20090148502A1 (en) 2006-10-23 2009-06-11 Hemo Nanoscience, Llc Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding
EP1935429A1 (en) 2006-12-22 2008-06-25 CSL Behring GmbH Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
CA2682405A1 (en) 2007-03-30 2008-10-09 Thrombodyne, Inc. Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue
SG174077A1 (en) 2007-04-13 2011-09-29 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
US8852558B2 (en) 2008-03-11 2014-10-07 Materials Modification, Inc. In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst
US20100086529A1 (en) 2008-10-08 2010-04-08 Mohammad Syed F Methods of making concentrated fibrinogen- and platelet-containing compositions
JP6000259B2 (ja) 2010-10-06 2016-09-28 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 止血障害治療用第ｉｉ因子およびフィブリノーゲン

Also Published As

Publication number Publication date
ES2625153T3 (es) 2017-07-18
WO2012045569A9 (en) 2016-01-07
SG10201508159SA (en) 2015-10-29
DK2624859T3 (en) 2017-06-06
JP6000259B2 (ja) 2016-09-28
SG188639A1 (en) 2013-05-31
KR20130136988A (ko) 2013-12-13
RU2606155C2 (ru) 2017-01-10
HUE033204T2 (en) 2017-11-28
MX2013003715A (es) 2013-09-26
US9433664B2 (en) 2016-09-06
CA2812888A1 (en) 2012-04-12
MX343784B (es) 2016-11-23
US20130280236A1 (en) 2013-10-24
RU2013120033A (ru) 2014-11-20
JP2013538863A (ja) 2013-10-17
AU2011313505A1 (en) 2013-04-11
BR112013008034A2 (pt) 2016-06-14
EP2624859B1 (en) 2017-03-01
EP2624859A1 (en) 2013-08-14
WO2012045569A1 (en) 2012-04-12
AU2011313505B2 (en) 2015-09-17
CN103221061A (zh) 2013-07-24

Similar Documents

Publication Publication Date Title
IL284067B (en) Derivatives of aminoglycosides, preparations containing them and their use for the treatment of genetic diseases
GB2478595B (en) Phytocannabinoids in the treatment of glioma
ZA201404929B (en) Compositions and methods for surface treatment with lipases
EP2717931A4 (en) ASSOCIATIONS AND RELATED METHODS
IL229431A0 (en) Preparations against cgrp and their use
PL2493957T3 (pl) Związane z mocznikiem alkoksysilany do stosowania w substancjach uszczelniających i klejach
IL216555A0 (en) Methods and compositions for the induction of hypothermia
IL236098A0 (en) Different fibronectin fragments or variants and uses thereof
EP2558137A4 (en) METHODS AND COMBINATION
HRP20182083T1 (hr) Nova kombinacija i uporaba
GB0903299D0 (en) Composition and methods
PL2531544T3 (pl) Polieterowe kopolimery blokowe i dostępne z nich kompozycje
EP2535410A4 (en) APTAMER FOR FGF2 AND USE THEREOF
PL2624859T3 (pl) Czynnik ii samodzielnie lub w skojarzeniu z dalszymi czynnikami do leczenia zaburzeń hemostazy powiązanych z koagulopatią z rozcieńczenia
GB201014969D0 (en) Improvements in or relating to burners
EP2968374A4 (en) METHODS AND COMPOSITIONS FOR IMPROVING OXYGEN RATE IN FABRICS
GB2477314B (en) Improvements in and relating to dressings
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
GB201004004D0 (en) Improvements in and relating to the consideration of evidence
EP2734543A4 (en) LACTOFERRIN FRAGMENTS AND USE THEREOF
GB2500357B (en) Combination and composition for treating obesity
HUE038120T2 (hu) Transzferrin autoimmun betegségek kezelésében és/vagy megelõzésében történõ alkalmazásra
ZA201304369B (en) Use of glycosaminoglycan lipote esters in the trichology field
IL220241A0 (en) Use of transferrin in treatment of beta-thalassemias
GB201007418D0 (en) Improved bandage and/or dressing